[go: up one dir, main page]

SI3394065T1 - Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega - Google Patents

Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega

Info

Publication number
SI3394065T1
SI3394065T1 SI201531588T SI201531588T SI3394065T1 SI 3394065 T1 SI3394065 T1 SI 3394065T1 SI 201531588 T SI201531588 T SI 201531588T SI 201531588 T SI201531588 T SI 201531588T SI 3394065 T1 SI3394065 T1 SI 3394065T1
Authority
SI
Slovenia
Prior art keywords
pyrrolopyrimidinone
methods
tetrahydropyranyl
amino
tetrahydropyranyl amino
Prior art date
Application number
SI201531588T
Other languages
English (en)
Inventor
Jean-Marc Lapierre
Sudharshan Eathiraj
Nivedita Namdev
Brian Schwartz
Yusuke Ota
Takayuki Momose
Tomoyuki Tsunemi
Hiroaki Inagaki
Kiyoshi Nakayama
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Publication of SI3394065T1 publication Critical patent/SI3394065T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201531588T 2015-12-23 2015-12-23 Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega SI3394065T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2015/000285 WO2017111787A1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP15911490.9A EP3394065B1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof

Publications (1)

Publication Number Publication Date
SI3394065T1 true SI3394065T1 (sl) 2021-08-31

Family

ID=59090991

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531934T SI3882250T1 (sl) 2015-12-23 2015-12-23 Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj
SI201531588T SI3394065T1 (sl) 2015-12-23 2015-12-23 Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201531934T SI3882250T1 (sl) 2015-12-23 2015-12-23 Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj

Country Status (28)

Country Link
EP (2) EP3882250B1 (sl)
JP (1) JP6634520B2 (sl)
KR (2) KR102547188B1 (sl)
CN (2) CN113307811B (sl)
AU (3) AU2015417922B2 (sl)
CA (1) CA3008446C (sl)
CY (1) CY1124210T1 (sl)
DK (2) DK3882250T3 (sl)
ES (2) ES2942743T3 (sl)
FI (1) FI3882250T3 (sl)
HR (2) HRP20210844T1 (sl)
HU (2) HUE055221T2 (sl)
IL (2) IL259938B (sl)
LT (2) LT3882250T (sl)
MA (1) MA56553B1 (sl)
MD (1) MD3882250T2 (sl)
MX (1) MX384022B (sl)
MY (1) MY193177A (sl)
PH (1) PH12018501390B1 (sl)
PL (2) PL3882250T3 (sl)
PT (2) PT3882250T (sl)
RS (2) RS64141B1 (sl)
RU (1) RU2715421C2 (sl)
SA (1) SA518391836B1 (sl)
SG (1) SG11201805154YA (sl)
SI (2) SI3882250T1 (sl)
WO (1) WO2017111787A1 (sl)
ZA (1) ZA201804091B (sl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3034010A1 (en) 2016-08-24 2018-03-01 Arqule, Inc. Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
KR20220016090A (ko) * 2019-05-31 2022-02-08 포천 파마슈티컬즈, 엘티디. 단백질 키나제 억제제로서 치환된 피롤로 [2, 3-b] 피리딘 및 피라졸로 [3,4-b] 피리딘 유도체
CN114728974B (zh) * 2019-11-13 2023-09-19 浙江龙传生物医药科技有限公司 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
EP4087845A4 (en) 2020-01-02 2024-01-24 Dizal (Jiangsu) Pharmaceutical Co., Ltd. BTK INHIBITORS
AU2021383227A1 (en) * 2020-11-17 2023-06-22 Fochon Biosciences, Ltd. SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技(苏州)有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
EP4339198A4 (en) * 2021-05-12 2025-06-11 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. CRYSTAL FORM OF A PYRROLOPYRIMIDINE COMPOUND AND METHOD FOR PREPARING THE CRYSTAL FORM
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
MX2012005827A (es) * 2009-11-18 2012-06-19 Plexxikon Inc Compuestos y metodos para la modulacion de cinasas, e indicaciones para ello.
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2014164729A1 (en) * 2013-03-12 2014-10-09 Arqule, Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
JP6495886B2 (ja) * 2013-03-15 2019-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Btk阻害剤としての複素環式芳香族化合物
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
AU2019201737B2 (en) 2020-03-05
PH12018501390A1 (en) 2019-02-27
PT3882250T (pt) 2023-04-21
WO2017111787A1 (en) 2017-06-29
KR102547188B1 (ko) 2023-06-26
MX2018007815A (es) 2019-07-04
CA3008446C (en) 2023-10-10
PT3394065T (pt) 2021-05-06
RS61887B1 (sr) 2021-06-30
CN108699062B (zh) 2021-06-29
EP3882250B1 (en) 2023-02-15
HRP20230379T1 (hr) 2023-06-23
LT3882250T (lt) 2023-05-25
MA56553B1 (fr) 2023-04-28
KR20230098690A (ko) 2023-07-04
CN108699062A (zh) 2018-10-23
DK3882250T3 (da) 2023-05-22
BR112018012828A2 (pt) 2018-12-04
RS64141B1 (sr) 2023-05-31
IL282572B (en) 2022-04-01
SA518391836B1 (ar) 2022-06-19
FI3882250T3 (fi) 2023-04-27
MD3882250T2 (ro) 2023-06-30
JP6634520B2 (ja) 2020-01-22
MA56553A (fr) 2022-04-27
RU2018126793A3 (sl) 2020-01-23
AU2020203690B2 (en) 2021-08-05
MY193177A (en) 2022-09-26
NZ743384A (en) 2024-05-31
AU2019201737A1 (en) 2019-04-04
IL259938A (en) 2018-07-31
IL259938B (en) 2021-05-31
ES2942743T3 (es) 2023-06-06
CN113307811B (zh) 2023-11-14
JP2018538349A (ja) 2018-12-27
HUE061761T2 (hu) 2023-08-28
AU2015417922A1 (en) 2018-06-28
ZA201804091B (en) 2019-03-27
SI3882250T1 (sl) 2023-07-31
EP3394065A1 (en) 2018-10-31
LT3394065T (lt) 2021-06-25
EP3882250A1 (en) 2021-09-22
DK3394065T3 (da) 2021-05-31
EP3394065A4 (en) 2019-07-10
CA3008446A1 (en) 2017-06-29
KR20180096753A (ko) 2018-08-29
IL282572A (en) 2021-06-30
SG11201805154YA (en) 2018-07-30
PL3394065T3 (pl) 2021-08-02
EP3394065B1 (en) 2021-04-07
ES2868884T3 (es) 2021-10-22
PH12018501390B1 (en) 2022-06-10
RU2715421C2 (ru) 2020-02-28
HUE055221T2 (hu) 2021-11-29
AU2020203690A1 (en) 2020-06-25
KR102746900B1 (ko) 2024-12-24
MX384022B (es) 2025-03-14
CN113307811A (zh) 2021-08-27
RU2018126793A (ru) 2020-01-23
PL3882250T3 (pl) 2023-09-11
CY1124210T1 (el) 2022-05-27
HRP20210844T1 (hr) 2021-07-09
AU2015417922B2 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
SI3394065T1 (sl) Tetrahidropiranil amino-pirolopirimidinon in postopki za uporabo le-tega
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
SI3328419T1 (sl) PD-1-vezavne molekule in postopki uporabe le-teh
IL254734B1 (en) Modified t cells and methods of making and using the same
IL280863A (en) Autotaxin inhibitors and uses thereof
IL251821A0 (en) Cannabis extracts and methods of preparing and using same
ZA201700241B (en) Mnk inhibitors and methods related thereto
SI3215601T1 (sl) Postopki za transdukcijo in obdelavo celic
DK3234151T3 (da) Systemer til svampegenommodificering og fremgangsmåder til anvendelse deraf
KR20180084891A (ko) 구조 조성물 및 방법
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3192869T3 (da) Isoleret oligonukleotid og anvendelse deraf i nukleinsyresekvensering
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
SI3319612T1 (sl) Oksisteroli in postopki za uporabo le-teh
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3172708T3 (da) Billetudstedelsesfremgangsmåde og -system
SI3290441T1 (sl) RGMA-vezavni protein in njegova uporaba
SI3265123T1 (sl) Protitelesa, uporabe in postopki
EP3640854C0 (en) IMPROVEMENTS FOR COUNTING DEVICES
SI3337506T1 (sl) Kombinacije in njihove uporabe
DE112015003841A5 (de) Di- und triphosphat-propharmaka
DK3180335T3 (da) Cytokrom-p450-inhibitorer og anvendelser deraf
DK3107376T3 (da) Svampelinje b12998-s39 og fremgangsmåder dertil og anvendelser herfor
DK3198005T3 (da) Fremgangsmåder til in vitro-oocytudvikling
DK3124611T3 (da) Aptamer til fgf2 og anvendelse deraf